A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

NCT01966224 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection

Sponsor

Immunomic Therapeutics, Inc.